214 related articles for article (PubMed ID: 34508776)
21. Microbiota-Immune Interactions in Ulcerative Colitis and Colitis Associated Cancer and Emerging Microbiota-Based Therapies.
Popov J; Caputi V; Nandeesha N; Rodriguez DA; Pai N
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768795
[TBL] [Abstract][Full Text] [Related]
22. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis.
Dang X; Xu M; Liu D; Zhou D; Yang W
PLoS One; 2020; 15(3):e0228846. PubMed ID: 32182248
[TBL] [Abstract][Full Text] [Related]
23. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
[TBL] [Abstract][Full Text] [Related]
24. Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy.
Schierová D; Březina J; Mrázek J; Fliegerová KO; Kvasnová S; Bajer L; Drastich P
Cells; 2020 Oct; 9(10):. PubMed ID: 33066233
[TBL] [Abstract][Full Text] [Related]
25. Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis.
Zhang YL; Cai LT; Qi JY; Lin YZ; Dai YC; Jiao N; Chen YL; Zheng L; Wang BB; Zhu LX; Tang ZP; Zhu RX
World J Gastroenterol; 2019 Jul; 25(25):3242-3255. PubMed ID: 31333315
[TBL] [Abstract][Full Text] [Related]
26. Microbial Signatures and Innate Immune Gene Expression in Lamina Propria Phagocytes of Inflammatory Bowel Disease Patients.
Dheer R; Davies JM; Quintero MA; Damas OM; Deshpande AR; Kerman DH; Sawyer WP; Pignac-Kobinger J; Ban Y; Fernandez I; Burgueno JF; Phillips MC; Abreu MT
Cell Mol Gastroenterol Hepatol; 2020; 9(3):387-402. PubMed ID: 31740421
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study.
Fang H; Fu L; Li X; Lu C; Su Y; Xiong K; Zhang L
Microb Cell Fact; 2021 Jan; 20(1):18. PubMed ID: 33468164
[TBL] [Abstract][Full Text] [Related]
28. Molecular profiling of mucosal tissue associated microbiota in patients manifesting acute exacerbations and remission stage of ulcerative colitis.
Walujkar SA; Kumbhare SV; Marathe NP; Patangia DV; Lawate PS; Bharadwaj RS; Shouche YS
World J Microbiol Biotechnol; 2018 May; 34(6):76. PubMed ID: 29796862
[TBL] [Abstract][Full Text] [Related]
29. Effects of soy milk consumption on gut microbiota, inflammatory markers, and disease severity in patients with ulcerative colitis: a study protocol for a randomized clinical trial.
Sadeghi O; Milajerdi A; Siadat SD; Keshavarz SA; Sima AR; Vahedi H; Adibi P; Esmaillzadeh A
Trials; 2020 Jun; 21(1):565. PubMed ID: 32576228
[TBL] [Abstract][Full Text] [Related]
30. Disease Severity and Immune Activity Relate to Distinct Interkingdom Gut Microbiome States in Ethnically Distinct Ulcerative Colitis Patients.
Mar JS; LaMere BJ; Lin DL; Levan S; Nazareth M; Mahadevan U; Lynch SV
mBio; 2016 Aug; 7(4):. PubMed ID: 27531910
[TBL] [Abstract][Full Text] [Related]
31. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis.
Suskind DL; Singh N; Nielson H; Wahbeh G
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):27-9. PubMed ID: 25162366
[TBL] [Abstract][Full Text] [Related]
32. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
Paramsothy S; Kamm MA; Kaakoush NO; Walsh AJ; van den Bogaerde J; Samuel D; Leong RWL; Connor S; Ng W; Paramsothy R; Xuan W; Lin E; Mitchell HM; Borody TJ
Lancet; 2017 Mar; 389(10075):1218-1228. PubMed ID: 28214091
[TBL] [Abstract][Full Text] [Related]
33. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.
Shaw KA; Bertha M; Hofmekler T; Chopra P; Vatanen T; Srivatsa A; Prince J; Kumar A; Sauer C; Zwick ME; Satten GA; Kostic AD; Mulle JG; Xavier RJ; Kugathasan S
Genome Med; 2016 Jul; 8(1):75. PubMed ID: 27412252
[TBL] [Abstract][Full Text] [Related]
34. Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis.
Leonardi I; Paramsothy S; Doron I; Semon A; Kaakoush NO; Clemente JC; Faith JJ; Borody TJ; Mitchell HM; Colombel JF; Kamm MA; Iliev ID
Cell Host Microbe; 2020 May; 27(5):823-829.e3. PubMed ID: 32298656
[TBL] [Abstract][Full Text] [Related]
35. 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside, a major bioactive component from Polygoni multiflori Radix (Heshouwu) suppresses DSS induced acute colitis in BALb/c mice by modulating gut microbiota.
He X; Liu J; Long G; Xia XH; Liu M
Biomed Pharmacother; 2021 May; 137():111420. PubMed ID: 33761623
[TBL] [Abstract][Full Text] [Related]
36. Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa.
Reshef L; Kovacs A; Ofer A; Yahav L; Maharshak N; Keren N; Konikoff FM; Tulchinsky H; Gophna U; Dotan I
Gastroenterology; 2015 Sep; 149(3):718-27. PubMed ID: 26026389
[TBL] [Abstract][Full Text] [Related]
37. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?
Berg D; Clemente JC; Colombel JF
Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):781-95. PubMed ID: 25665875
[TBL] [Abstract][Full Text] [Related]
38. Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis.
He XX; Li YH; Yan PG; Meng XC; Chen CY; Li KM; Li JN
World J Gastroenterol; 2021 Jul; 27(28):4722-4737. PubMed ID: 34366632
[TBL] [Abstract][Full Text] [Related]
39. Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.
Carlucci C; Petrof EO; Allen-Vercoe E
EBioMedicine; 2016 Nov; 13():37-45. PubMed ID: 27720396
[TBL] [Abstract][Full Text] [Related]
40. Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production.
Wang MX; Lin L; Chen YD; Zhong YP; Lin YX; Li P; Tian X; Han B; Xie ZY; Liao QF
Pharmacol Res; 2020 Sep; 159():104978. PubMed ID: 32485282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
